Table 2:
Characteristics of the Included Studies
| Author, Year | Country | Sample Size, N | EoL Population | Mean Age, y (SD) I/C | Male, n (%) I/C | Patient Care Setting |
|---|---|---|---|---|---|---|
| Pelayo-Alvarez et al, 2013 (14) | Spain | 117 | Advanced cancer | 69 (1) / 70 (11) | 39 (62) / 31 (57) | Primary care |
| Curtis et al, 2013 (15) | United States | 1,717 | Advanced chronic diseasea | 65 (14) / 66 (14) | 455 (59) / 534 (56) | Hospital |
| Curtis et al, 2011 (16)b | United States | 396 | Advanced chronic diseasea | 58 (15) / 59 (15) | 66 (37) / 55 (26) | Hospital |
| Meyers et al, 2011 (17) | United States | 441 | Advanced cancer | NR / NR | NR / NR | Hospital |
| Bakitas et al, 2009 (18) | United States | 279 | Advanced cancer | 65 (10) / 65 (12) | 90 (62) / 78 (58) | Hospital |
| McMillan et al, 2006 (19) | United States | 220 | Advanced cancer | 71 (11) / 70 (13) | 56 (63)/ 51 (56) | Community-dwelling, hospice care |
Abbreviations: C, control; EoL, end of life; I, intervention; NR, not reported; SD, standard deviation.
a
Included chronic obstructive pulmonary disease, congestive heart failure, end-stage liver disease, and terminal cancer.
b
Cluster randomized trial.